Kepler Capital Markets Analysts Give Sartorius (SRT3) a €107.00 Price Target

Kepler Capital Markets set a €107.00 ($124.42) target price on Sartorius (FRA:SRT3) in a research note issued to investors on Thursday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.

A number of other research analysts also recently commented on the stock. Deutsche Bank set a €150.00 ($174.42) target price on shares of Sartorius and gave the company a neutral rating in a research report on Thursday, April 11th. Hauck & Aufhaeuser set a €130.00 ($151.16) target price on shares of Sartorius and gave the company a sell rating in a research report on Thursday, April 4th. Berenberg Bank set a €110.00 ($127.91) target price on shares of Sartorius and gave the company a neutral rating in a research report on Tuesday, January 29th. UBS Group set a €147.00 ($170.93) target price on shares of Sartorius and gave the company a neutral rating in a research report on Wednesday, February 20th. Finally, Nord/LB set a €90.00 ($104.65) target price on shares of Sartorius and gave the company a sell rating in a research report on Tuesday, February 5th. Five equities research analysts have rated the stock with a sell rating and four have given a hold rating to the company. The company currently has a consensus rating of Sell and an average target price of €122.89 ($142.89).

FRA SRT3 opened at €152.90 ($177.79) on Thursday. Sartorius has a 12 month low of €71.00 ($82.56) and a 12 month high of €124.70 ($145.00).

About Sartorius

Sartorius Aktiengesellschaft supplies pharmaceutical and laboratory equipment worldwide. It operates in two divisions, Bioprocess Solutions, and Lab Products & Services. The company offers products for suspension cell analysis and live-cell analysis inside incubator for oncology, immuno-oncology, antibody discovery, neuroscience, and stem cell research; cell culture media, including antibody and recombinant protein, viral vaccines, and regenerative medicine media, as well as general media and downstream buffers; and multi-parallel, single-use, benchtop, stainless steel, microbial, and cell culture bioreactors, as well as cell culture expansion systems and software applications for bioreactors.

Recommended Story: What is channel trading?

Analyst Recommendations for Sartorius (FRA:SRT3)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.